RecruitingPHASE2, PHASE3NCT07131319

SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC

Studying Radiation-induced disorder

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Second Affiliated Hospital of Nanchang University
Intervention
Spatially Fractionated Radiotherapy (SFRT)(other)
Enrollment
30 target
Eligibility
18-85 years · All sexes
Timeline
20252026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07131319 on ClinicalTrials.gov

Other trials for Radiation-induced disorder

Additional recruiting or active studies for the same condition.

See all trials for Radiation-induced disorder

← Back to all trials